CEP

YM BioSciences Announces Preclinical Data Confirming Nimotuzumab Binds to the EGF Receptor and Potentiates Radiotherapy

MISSISSAUGA, ON, July 09, 2007 /PRNewswire-FirstCall/ - YMBioSciences Inc. , an oncology company that identifies, developsand commercializes differentiated products for patients worldwide,today announced that a study presented by investigators from KinkiUniversity School of Medicine and Kyoto University at the 11thmeeting of The Japanese Association for Molecular Target Therapy ofCancer...

Chi-Med Announces Positive Phase II Proof-of-Concept Data for HMPL-004 in Ulcerative Colitis

LONDON, 2 July2007: Chi-Med, the Hutchison Whampoa backed pharmaceutical andhealthcare Group, today announces positive results for its Phase IIproof-of-concept study...

Lupus Foundation of America Statement on Results for Clinical Study of CellCept Released by Aspreva Pharmaceutical Company

Statement by Sandra C. Raymond, President & CEO of the LupusFoundation of America, Inc. WASHINGTON, June 27, 2007 /PRNewswire-USNewswire/ -- The LupusFoundation of America, Inc. and more than 1.5 million Americanswith lupus have been awaiting the preliminary findings of the PhaseIII clinical trials for CellCept(R), a potential treatment forlupus kidney disease being tested by Aspreva...

Aspreva and Roche Announce Preliminary Results for Phase III Study Evaluating CellCept in Lupus Nephritis

VICTORIA, BC, Canada and BASEL, Switzerland, June 27 /CNW/ -Aspreva Pharmaceuticals Corporation (NASDAQ: ASPV; TSX: ASV) andRoche today released preliminary results for a clinical trialcomparing CellCept (oral mycophenolate mofetil, MMF) to intravenouscyclophosphamide (IVC), which is the current standard of care, forinducing treatment response in the induction phase of patientssuffering fro...

Phosphagenics Announces Positive Proof of Concept Results from Studies Utilizing Company's Dermal Drug Delivery Technology

MELBOURNE, Australia, June 25, 2007 /PRNewswire-FirstCall/ --Phosphagenics Limited (AIM: PSG) announced today positive resultsfrom pre-clinical studies of its TPM-02 dermal drug deliverytechnology formulated with retinoic acid, a leading topicaltreatment for severe acne and an active ingredient used inanti-aging cosmetics. The proof of concept studies showed a three-fold increase i...

VeroScience Late-Breaking Abstract on Cycloset (A Quick Release Formulation of Bromocriptine Mesylate) Accepted for Poster Presentation at American Diabetes Association 67th Scientific Sessions

TIVERTON, R.I., June 18, 2007 /PRNewswire/ -- VeroScience, LLC,a privately held biotechnology and healthcare product developmentcompany, announced today that its late-breaking abstract has beenaccepted as a poster presentation at the 67th Scientific Sessionsof the American Diabetes Association in Chicago, Ill. The abstract,entitled, "Effects of Timed Cycloset(TM) (A Quick ReleaseFormulat...

Investigational Study Demonstrated a Re-Establishment of Clinical Improvement with Orencia (Abatacept) in Children with Juvenile Idiopathic Arthritis upon Re-Introduction of Therapy

BARCELONA, Spain, June 15, 2007 /PRNewswire-FirstCall/ --Bristol-Myers Squibb Company today announced results regarding theefficacy and safety of ORENCIA(R) (abatacept) from the open-labelphase of an ongoing investigational study in children with juvenileidiopathic arthritis (JIA) who have had an inadequate response toone or more disease-modifying anti- rheumatic drugs (DMARDs), suchas m...

Savient Pharmaceuticals Announces Acceptance of Two Gout-Related Abstracts for Poster Presentation at the European League Against Rheumatism (EULAR) 2007 Annual Congress

EAST BRUNSWICK, N.J.--(BUSINESS WIRE)--Jun 6, 2007 - SavientPharmaceuticals, Inc. (NASDAQ: SVNT) announced today that twoabstracts exploring Phase 2 Puricase(R) (PEG-uricase) data andquality of life in treatment-failure gout patients will bepresented at the European League Against Rheumatism (EULAR) 2007Annual Congress taking place June 13 - 16th in Barcelona, Spain.Puricase is a PEGylated...

Evotec AG (DE) - Evotec Reports Positive Proof-of-Concept Top-Line Results with ...

- Both co-primary endpoints, Wake After Sleep Onset and TotalSleep Time, and key secondary endpoints, including Latency toPersistent Sleep, were met at both doses - Evotec to host aconference call at 4pm CET (3pm UK time, 10am EST) today HAMBURG, Germany | OXFORD, England, June 4, 2007-- Evotec AG(Frankfurt Stock Exchange: EVT) announced today positive top-lineresults from its firs...

Updated Overall Survival Data From Pivotal Herceptin Adjuvant Studies in HER2-Positive Breast Cancer

CHICAGO--(BUSINESS WIRE)--Jun 4, 2007 - Genentech, Inc. (NYSE:DNA)today announced updated results from a joint analysis of two PhaseIII clinical trials studying Herceptin(R) (trastuzumab) for theadjuvant treatment of HER2-positive breast cancer. Data presentedat the 43rd Annual Meeting of the American Society of ClinicalOncology (ASCO) showed that, with median follow-up of nearly threeyears...

Evotec Reports Positive Proof-of-Concept Top-Line Results with Insomnia Drug Candidate EVT 201

Both Co-Primary Endpoints, Wake After Sleep Onset and Total SleepTime, and Key Secondary Endpoints, Including Latency to PersistentSleep, Were Met at Both Doses HAMBURG, Germany and OXFORD, England, June 04, 2007/PRNewswire-FirstCall/ -- Evotec AG announced today positivetop-line results from its first phase II clinical trial of EVT 201in patients with chronic primary insomnia. EVT 201 is...

ZymoGenetics Reports Results From Atacicept Phase 1b Clinical Trial in B-Cell Chronic Lymphocytic Leukemia

SEATTLE, June 04, 2007 /PRNewswire-FirstCall/ -- ZymoGenetics,Inc. today announced that interim findings were presented from aPhase 1b clinical trial with atacicept in B-cell chroniclymphocytic leukemia (B-CLL) at the American Society of ClinicalOncology (ASCO) 2007 annual meeting. The study included intravenousadministration of higher doses than had been tested in previousstudies. <...

Investigational Cancer Drug Pertuzumab Shows Promising Results in Advanced Breast Cancer When Combined with Herceptin

Investigational cancer drug Pertuzumab shows promising results inadvanced breast cancer when combined with Herceptin Phase IIIdevelopment initiated BASEL, Switzerland, June 4, 2007-Early clinical results fromRoche's trial of the exciting new cancer medicine pertuzumab, a HERdimerisation inhibitor, show substantial anti-tumour activity inpatients with pre-treated HER2 positive breast cance...

Six Abstracts Featuring Exelixis Compounds Accepted At ASCO Conference

- Phase I data from XL880, Phase II data from XL999 studiesscheduled for presentation during oral, poster sessions - SOUTH SAN FRANCISCO, May 30, 2007 /PRNewswire-FirstCall/ --Exelixis, Inc. announced today that data from clinical trials ofthe company's investigational compounds XL880 and XL999 will bepresented at the 2007 American Society of Clinical Oncology AnnualMeeting (ASCO), which...

Bentley Late Breaking Abstract Accepted for Poster Presentation at American Diabetes Association Scientific Sessions

EXETER, N.H.--(BUSINESS WIRE)--May 24, 2007 - BentleyPharmaceuticals, Inc. (NYSE: BNT), a specialty pharmaceuticalcompany, today announced that a late breaking abstract sponsored bythe Company has been accepted for a poster presentation at theAmerican Diabetes Association 67th Scientific Sessions in Chicago.The abstract, entitled "Results of a Randomized, Single-Dose,2/3-Way Crossover Compa...

Hypertension Education Foundation Survey Results Announced At American Society For Hypertension Annual Meeting Suggests Improved Control Of High Blood Pressure, But Misconceptions Still Exist

Findings Show Compliance with Medication Instructions butUnderscore Need for Improved Patient Communication, LifestyleManagement and More Healthcare Provider Efforts to Control ElevatedBlood Pressure NEW YORK, May 19, 2007 /PRNewswire/ -- Results of a surveyconducted by Harris Interactive(R) for the Hypertension EducationFoundation (HEF) were presented at the American Society ofHypertens...

Early Results of the CellCept Spare the Nephron Study Examine Kidney Function

SAN FRANCISCO, May 07, 2007 /PRNewswire/ -- Interim results froma multicenter trial investigating a novel kidney-sparing treatmentprotocol using CellCept(R) (mycophenolate mofetil) were presentedat the American Transplant Congress. This and other Spare theNephron (STN) trials in kidney and liver transplant recipientsexamine ways to prevent rejection without damaging kidneys. As tra...

EpiCept Corporation to Present New NP-1 Data at American Pain Society Meeting

Supports Local Mechanism of Action of NP-1 in Neuropathic Pain TARRYTOWN, N.Y., May 03, 2007 /PRNewswire-FirstCall/ -- EpiCeptCorporation announced today that it will present new data forEpiCept(TM) NP-1 on Thursday, May 3, 2007 at the 26th AnnualScientific Meeting of the American Pain Society in Washington D.C.EpiCept NP-1 is a patented topical cream formulation of twoFDA-approved drugs,...

Cephalon Presents Positive Results for Fentora in Breakthrough Pain Associated with Neuropathic Conditions

All Efficacy Measures Reached Statistical Significance FRAZER, Pa., May 01, 2007 /PRNewswire-FirstCall/ -- A Cephalon,Inc. Phase 3 clinical trial presented today at the 59th AnnualMeeting of the American Academy of Neurology in Boston highlightsdata demonstrating that FENTORA(R) (fentanyl buccal tablet) [C-II]is beneficial for the treatment of breakthrough pain in patientswith...

Amsterdam Molecular Therapeutics BV to present preclinical proof-of-concept data on its gene therapy AMT-020 to treat acute intermittent porphyria

The research, done in collaboration with the Centro deInvestigación Médica Aplicada (CIMA) at theUniversity of Navarra, Pamplona, Spain, is being presented atPorphyrins and Porphyrias Congress, Rotterdam, the Netherlands. AMSTERDAM, the Netherlands, May 1st 2007 - Amsterdam MolecularTherapeutics BV (AMT), a leader in the field of human gene therapy,will today present...

SciClone Announces ZADAXIN and SCV-07 Abstracts Accepted at ASCO

SAN MATEO, CA — April 27, 2007 — SciClonePharmaceuticals, Inc. (NASDAQ: SCLN) today announced that thefollowing abstracts have been accepted for the Annual Meeting ofthe American Society of Clinical Oncology in Chicago, Illinois onJune 1-5, 2007: ZADAXIN® (thymalfasin, thymosin alpha 1) PosterPresentation A large first-line, randomized, dose-finding, ph...

Human Genome Sciences Reports Growing Evidence That Its TRAIL Receptor Antibodies Have Significant Potential in the Treatment of a Broad Range of Cancers

- Journal of Clinical Oncology publishes first clinical study ofHGS-ETR1 - ROCKVILLE, Md., April 27, 2007 /PRNewswire-FirstCall/ -- HumanGenome Sciences, Inc. today reported that clinical and preclinicalevidence continues to emerge demonstrating that its TRAIL receptorantibodies, HGS-ETR1 (mapatumumab) and HGS-ETR2 (lexatumumab), havesignificant potential for use in the treatment of a bro...

First Controlled Large-Scale Intervention Angiotensin Receptor Blocker (ARB) Trial in a Japanese Population, JIKEI HEART Study Demonstrates Significant Reduction in Blood Pressure and Protection of Organs with Valsartan

Unprecedented Evidence for the Effectiveness of HypertensionTreatment Valsartan in Preventing Cardiovascular Events in JapanesePatients TOKYO, April 26, 2007 /Xinhua-PRNewswire/ -- The clinicaloutcomes of the JIKEI HEART Study, the large-scale clinical trialheaded by the Jikei University School of Medicine, was todaypublished in the internationally renowned medical journal TheLancet. The...

Acorda Therapeutics to Host Analyst and Investor Reception

HAWTHORNE, N.Y.--(BUSINESS WIRE)--Apr 25, 2007 - AcordaTherapeutics, Inc.(R) (Nasdaq: ACOR) today announced that Dr.Lauren Krupp, Professor of Neurology at Stony Brook University,will present data from Acorda's Phase 3 clinical trial ofFampridine-SR in multiple sclerosis at their analyst and investorreception on May 2, 2007. This reception will follow a presentationof this data at the Ameri...

Positive Results Using Affitech-Identified Human Antibody That Blocks VEGF Binding to VEGF Receptor 2 in Preclinical Cancer Model Reported by Peregrine

OSLO, Norway--(BUSINESS WIRE)--Apr 23, 2007 - Affitech AS, thehuman antibody therapeutics company announced today that PeregrinePharmaceuticals, Inc. reported positive in vivo test results of R3,a fully human monoclonal antibody developed by Affitech, in apancreatic cancer model at the recently concluded Centennial AnnualMeeting of the American Association for Cancer Research (AACR). R3has...

Mode of Action of EpiCept-Licensed Cancer Compound Profiled at AACR

Myriad Genetics Presents Studies Characterizing Vascular DisruptionCapabilities of Azixa(TM) TARRYTOWN, N.Y., April 20, 2007 /PRNewswire-FirstCall/ --EpiCept Corporation reported today that studies characterizing adual mode of action for Azixa(TM), a compound licensed by theCompany to Myriad Genetics, Inc. for the treatment of primary andsecondary brain tumors, were presented at the annua...

Portola Pharmaceuticals Presents Positive Phase I Data of Its ADP Receptor Antagonist at the American College of Cardiology

NEW ORLEANS, March 28, 2007 /PRNewswire/ -- PortolaPharmaceuticals, Inc. presented Phase I data of its ADP receptorantagonist at the of Cardiology's (ACC) 56th Annual ScientificSession this week. Portola's reversible antiplatelet compound,PRT060128, appeared safe and well-tolerated in this study andachieved high-level platelet inhibition. Portola presented the data in a poster sess...

Corcept Therapeutics Announces Phase 3 Study Evaluating Corlux for Psychotic Major Depression Misses Primary Endpoint

STATISTICALLY SIGNIFICANT CORRELATION BETWEENPLASMA LEVELS AND CLINICAL OUTCOME ACHIEVED DURING TREATMENT Management will host a conference call and livewebcast on March 20, 2007 at 9:00 a.m. EDT MENLO PARK, Calif. (March 19, 2007) – Corcept TherapeuticsIncorporated (NASDAQ: CORT), today announced that Study 06, thelast of three Phase 3 trial...

ArQule Announces Acceptance of Clinical Data on ARQ 197, c-Met Inhibitor, for Oral Presentation at ASCO

WOBURN, Mass.--(BUSINESS WIRE)--Mar 14, 2007 - ArQule, Inc.(NASDAQ: ARQL) today announced that the American Society ofClinical Oncology (ASCO) has accepted for oral presentation theCompany's abstract for ARQ 197 (A Phase 1 Dose Escalation Study ofARQ 197, a Selective Inhibitor of the c-Met Receptor in Patientswith Metastatic Solid Tumors) at the 43rd ASCO Annual Meeting, June1-5, 2007, in C...

Schering-Plough Announces Presentation of Phase II Trial Results for Novel Oral Thrombin Receptor Antagonist at the 2007 Annual Meeting of The American College of Cardiology/i2 Summit

KENILWORTH, N.J., March 12, 2007 /PRNewswire-FirstCall/ --Schering-Plough Corporation announced today that results of thePhase II trial of its novel oral thrombin receptor antagonist (TRA)SCH 530348 will be presented at the 2007 annual Scientific Sessionsof the of Cardiology (ACC.07)/Innovation in Intervention (i2)Summit, March 24-27 in New Orleans. The Phase II trial, referred toas the...

Weight Management is Not Enough for Cannabinoid Type 1 (CB1) Receptor Antagonists to Become a Commercial Success

Huge clinical development program of first-in-class CB1antagonist rimonabant to show benefits beyond weight reduction andavoid image as life-style drug BARCELONA, Spain | March 08, 2007 | The Business Intelligencefirm La Merie S.L. reported today that Sanofi-Aventis’first-in-class CB1 antagonist Acomplia (rimonabant) has at leastfive competitors in clinical stages up to phase...

American Society of Clinical Oncology (ASCO) Accepts New Data on AVR118 for Publication in 2007 Abstract Book

YONKERS, N.Y.--(BUSINESS WIRE)--Mar 7, 2007 - Advanced ViralResearch Corp. (OTC Bulletin Board: ADVR) a bio-pharmaceuticalcompany, announced today that new information on AVR118 has beenaccepted for publication in the 2007 Proceedings of the AmericanSociety of Clinical Oncology (ASCO) Abstract publication. Thispublication will be distributed to the nearly 25,000 oncologypractioners who will...

Accentia Biopharmaceuticals Scientific Presentations Demonstrate Increasing Acceptance of Fungal Etiology of Chronic Sinusitis at the Annual Meeting of the American Academy of Allergy, Asthma, and Immunology

TAMPA, Fla.--(BUSINESS WIRE)--Mar 7, 2007 - AccentiaBiopharmaceuticals, Inc. (NASDAQ: ABPI), presented three posters atthe Annual Meeting of the American Academy of Allergy, Asthma, andImmunology from February 23 - 27, 2007 in San Diego, CA. Theposters discussed findings from a survey of 202 otolaryngologists(ENTs) and allergists in the U.S., U.K., France, and Germany on theburden of chroni...

POZEN Announces Positive Outcome for PA 325 Proof of Concept Study

CHAPEL HILL, N.C.--(BUSINESS WIRE)--Mar 6, 2007 - POZEN Inc.(NASDAQ: POZN), today announced top-line results of its "SaferAspirin" PA 325 proof-of-concept study conducted during the fourthquarter of 2006. PA 325 is a patented formulation of 325mg ofaspirin surrounded by a 20mg coating of an immediate releaseformulation of a proton pump inhibitor. The PA 325, 28 day study, involved two gro...